Examkin

Question

Difficulty: MediumInfectious Diseases

An adult male patient is evaluated during morning rounds on the surgical ward. He is currently on postoperative day 3 following an emergent partial colectomy for a perforated diverticulum. At the time of presentation, he met criteria for sepsis and was empirically started on intravenous meropenem. His clinical course has steadily improved following source control. Today, his temperature is 37.1°C (98.8°F), blood pressure is 122/78 mmHg, and pulse is 76/min. He is tolerating a soft diet, and his bowel function has returned. His white blood cell count has decreased from 18,000/mm³ on admission to 8,500/mm³. Intraoperative peritoneal fluid cultures now demonstrate heavy growth of Escherichia coli and Bacteroides fragilis. Susceptibility testing for the E. coli isolate shows resistance to ampicillin but susceptibility to ciprofloxacin, ceftriaxone, and trimethoprim-sulfamethoxazole. Admission blood cultures have remained sterile. Which of the following is the most appropriate next step in pharmacotherapy?

  1. Transition to oral ciprofloxacin and oral metronidazoleAnswer
  2. B
    Continue intravenous meropenem
  3. C
    Transition to intravenous piperacillin-tazobactam
  4. D
    Transition to oral ciprofloxacin
  5. E
    Transition to intravenous ceftriaxone and intravenous metronidazole

Answer

Transition to oral ciprofloxacin and oral metronidazole
The most appropriate management is transitioning to an oral regimen of ciprofloxacin and metronidazole. The patient has a complicated intra-abdominal infection but has achieved source control and is now clinically stable with a functioning gastrointestinal tract. Antimicrobial stewardship principles strongly emphasize de-escalating from broad-spectrum empiric intravenous therapy (such as meropenem) to a targeted regimen based on culture data. The isolated Escherichia coli is susceptible to ciprofloxacin, and metronidazole provides targeted, highly effective coverage against Bacteroides fragilis. Both agents possess excellent oral bioavailability (approaching 100%), allowing for a safe transition from intravenous to oral therapy. This step-down facilitates the removal of intravenous catheters, minimizes the risk of line-associated complications, and hastens hospital discharge.

Step-by-Step Solution

1
Analyze the patient's clinical trajectory and current status.
The patient is clinically stable, afebrile, and tolerating an oral diet following source control for a complicated intra-abdominal infection.
Determining clinical stability is necessary to decide if a transition from intravenous to oral therapy is safe.
2
Review the microbiological data and required pathogen coverage.
Cultures grew Escherichia coli (susceptible to ciprofloxacin) and Bacteroides fragilis.
Any selected antimicrobial regimen must cover both the aerobic gram-negative rod and the obligate anaerobe.
3
Apply antimicrobial stewardship principles to select the optimal regimen.
De-escalate from empiric meropenem to a targeted, narrow-spectrum regimen. Choose highly bioavailable oral agents (ciprofloxacin and metronidazole) to facilitate prompt intravenous catheter removal.
Stewardship minimizes collateral damage to the microbiome, prevents highly resistant organisms, and reduces hospital-acquired complications like phlebitis or line infections.

Key Concept

Antimicrobial stewardship dictates transitioning from broad-spectrum intravenous therapy to targeted, highly bioavailable oral therapy in clinically stable patients with known culture susceptibilities.
Rate this question

Topics

Infectious Diseases

More questions from this topic